Students' Research Committee, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
Nutrition Research Center, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
Complement Ther Med. 2020 Mar;49:102290. doi: 10.1016/j.ctim.2019.102290. Epub 2019 Dec 26.
The current study evaluated the effects of green coffee extract (GCE) on serum lipid profile and adiponectin levels in patients with nonalcoholic fatty liver disease (NAFLD).
This randomized, double-blind, placebo-controlled clinical trial was conducted on NAFLD patients aged 20-60 years and body mass index (BMI) of 25-35 kg/m.
Patients were recruited from the Bahman poly-clinic (Neyshabur, Iran) between January and June 2016.
The study subjects were randomly assigned to receive a daily dose of 400 mg GCE (n = 24) or placebo (n = 24) for eight weeks.
Serum liver enzyme levels, lipid profile, adiponectin concentrations, and hepatic steatosis grade were measured for all patients at baseline and the end of the trial.
GCE supplementation significantly reduced BMI [mean difference (MD): -0.57 and 95 % confidence interval (CI): -0.84 to -0.29, P < 0.001] and increased serum high-density lipoprotein cholesterol (MD: 7.06, 95 % CI: 0.25-13.87, P < 0.05) compared to the control group. Serum total cholesterol decreased significantly within the GCE group (MD: -13.33, 95 % CI: -26.04 to -0.61, P < 0.05). Triglyceride levels reduced significantly in GCE group compared to the placebo group (MD: -37.91; 95 % CI: -72.03 to -3.80; P = 0.03). However, this reduction was not significant when was further adjusted for mean changes in BMI and daily energy intake (MD: -23.43; 95 % CI: -70.92 to 24.06; P = 0.32). Hepatic steatosis grade, liver enzymes, and adiponectin levels did not show significant differences between the two groups after the intervention.
GCE supplementation improved serum lipid profile and BMI in individuals with NAFLD. GCE may be useful in controlling NAFLD risk factors.
本研究评估了绿咖啡提取物（GCE）对非酒精性脂肪性肝病（NAFLD）患者血清脂质谱和脂联素水平的影响。
这是一项随机、双盲、安慰剂对照的临床试验，纳入了年龄在 20-60 岁之间、体重指数（BMI）为 25-35kg/m 的 NAFLD 患者。
患者于 2016 年 1 月至 6 月期间在伊朗尼沙布尔的巴曼综合诊所招募。
研究对象随机分配接受每日 400mg GCE（n=24）或安慰剂（n=24）治疗 8 周。
所有患者在基线和试验结束时均测量血清肝酶水平、脂质谱、脂联素浓度和肝脂肪变性程度。
与对照组相比，GCE 补充剂可显著降低 BMI[平均差异（MD）：-0.57，95%置信区间（CI）：-0.84 至-0.29，P<0.001]和血清高密度脂蛋白胆固醇（MD：7.06，95%CI：0.25-13.87，P<0.05）。与对照组相比，GCE 组的血清总胆固醇显著下降（MD：-13.33，95%CI：-26.04 至-0.61，P<0.05）。与安慰剂组相比，GCE 组的甘油三酯水平显著降低（MD：-37.91；95%CI：-72.03 至-3.80；P=0.03）。然而，当进一步根据 BMI 和每日能量摄入的平均变化进行调整时，这种降低并不显著（MD：-23.43；95%CI：-70.92 至 24.06；P=0.32）。干预后两组患者的肝脂肪变性程度、肝酶和脂联素水平无显著差异。
GCE 补充剂可改善 NAFLD 患者的血清脂质谱和 BMI。GCE 可能有助于控制 NAFLD 的危险因素。
